Singapore, March 14 -- ENCell Co., Ltd., a South Korean biotech company specialising in advanced biopharmaceutical contract development and manufacturing organizations (CDMO) and novel drug development, has signed a Memorandum of Understanding (MoU) for collaboration in the field of cell and gene therapy (CGT) with Cell Resources Corporation (CRC)- a member of Japan's leading pharmaceutical companyAlfresa Group, designed to drive the group's expansion into the CGT market.

Following the MoU, the two companies plan to discuss a contractual agreement for the transfer of ENCell's CDMO technology and expertise. They will also actively seek opportunities to build network among their respective clients by maintaining a close partnership.

Notab...